Weekly Market Review — Week of July 27, 2026

Weekly Market Review — Week of July 27, 2026

Published by Bihzuun Research  |  Covering the trading week of July 27–31, 2026

Week in Review: Market Performance

The week of July 27–31, 2026 delivered a compressed, high-intensity sequence of macro and earnings catalysts that kept institutional desks on edge from open to close every session. The three major indices posted mixed-to-positive results on a weekly basis, but the headline numbers obscure a notable intra-week bifurcation: strong early momentum from earnings beats across the defense and technology sectors gave way to mid-week consolidation ahead of the Federal Reserve decision, followed by a modest relief rally into Friday’s close.

Index Summary

Analyst Note: Bihzuun Research does not fabricate or estimate index closing prices. Precise weekly index return figures for the July 27–31, 2026 period are not confirmed in our research data set for this publication. We present qualitative context below based on the catalysts that structured the week, and readers should cross-reference terminal or brokerage data for exact index closes.

Key Weekly Macro Narrative

• Monday — AZN Q2 Earnings (July 27): AstraZeneca opened the week with a material earnings beat — core EPS of $2.63 versus $2.48 consensus, an 18% constant-currency outperformance — that set a positive tone for the healthcare and biopharma complex. The China revenue decline of 13% tempered the initial reaction, keeping the stock range-bound rather than surging. The imminent camizestrant FDA decision (late August) remained the dominant narrative overhang.
• Tuesday — Rate Anxiety Into FOMC (July 28): Micron’s ongoing extraordinary momentum (market price $900.20, driven by FQ4 revenue guidance of $50B ± $1B and 86% gross margin guidance) kept the semiconductor complex elevated, but rising caution ahead of the Wednesday FOMC decision produced modest broad-market consolidation. The fundamental divergence between MU’s market price and normalized intrinsic value anchors remained the defining analytical tension of the semiconductor coverage universe.
• Wednesday — FOMC Decision + GD Earnings (July 29): The dual catalyst day. General Dynamics reported Q2 2026 earnings before market open against consensus of $3.97 EPS on $13.54B revenue — contributing to the positive defense earnings read-through already established by Lockheed Martin (+10.5% YoY, 3.8% beat) and RTX (+14.5% YoY, 7.8% beat, stock surged) earlier in the cycle. The FOMC rate decision — the fourth consecutive hold in this cycle — was received as broadly neutral, with investors parsing Chair Warsh’s language carefully for any signal regarding the August 27–29 Jackson Hole trajectory. No hawkish surprise materialised, removing the acute rate shock risk that had been flagged as the primary macro risk for high-multiple technology positions including ANET and MU.
• Thursday — GDP Advance Estimate + ANET Report Date (July 30): The BEA Q2 2026 GDP advance estimate was the week’s most consequential macro data point for the longer-duration growth equity complex. Arista Networks, covered in Thursday’s brief, faced an earnings binary on August 4 (three trading days out), making Thursday’s session a positioning and risk-management day for ANET holders. The GDP print’s direction — resilient or contractionary — set the tone for the August earnings week entry conditions.
• Friday — Cboe Earnings + Monthly Close (July 31): Cboe Global Markets reported Q2 2026 earnings before market open on Friday against consensus of $708.5M revenue (+20.6% YoY) and EPS of $3.45. Cboe’s narrative — a market misreading its competitive positioning in the emerging prediction markets category — represented the week’s most nuanced investment call. The 25% drawdown from highs on disruption fears, combined with a 5.8% margin of safety to composite intrinsic value and a perfect historical growth score of 100/100, made Friday’s earnings event the most asymmetric risk/reward binary of the week for the positions covered.

Our Picks This Week: Recommendations Summary

The table below captures every stock on which Bihzuun Research published formal coverage during the week of July 27–31, 2026, together with the entry price at the time of publication, the reported current price as of the relevant report date, and a note on subsequent price movement where data permits. All prices are as reported in the individual daily briefs.

Important Note on Weekly Price Change Column: Because several of these positions were initiated on the same day as earnings reports (GD on July 29, CBOE on July 31) and one has an earnings event three trading days forward (ANET on August 4), intra-week “gain/loss since recommendation” figures carry limited analytical signal and have been excluded to avoid presenting ephemeral noise as meaningful performance data. Bihzuun Research will track all five positions on a forward basis in the weekly reviews that follow, reporting percentage changes from the publication-date entry price in subsequent installments.

What Worked and What Didn’t

What Worked

• AZN — Thesis Validation on Earnings Day (Monday). Publishing the AstraZeneca Strong Buy on the morning of Q2 2026 results proved analytically well-timed. The 18% constant-currency EPS beat confirmed the Growth scorecard sub-score of 99/100 as a genuine signal of structural momentum rather than one-quarter noise. More importantly, the Earnings Power Value floor analysis — placing the EPV at $165 against a current price of $169.26 — correctly identified that investors at current levels were paying almost no premium above zero-growth intrinsic value for one of the richest growth pipelines in global biopharma. The multi-model convergence between the DCF ($196.17) and Comparable Companies ($194.61) at essentially the same price level provided the kind of cross-methodology validation that gives institutional investors confidence in a target rather than forcing a judgment call between divergent outputs. The thesis held on earnings day. The camizestrant FDA decision remains the key near-term binary, but the earnings print removed execution uncertainty from the near-term investment case.
• GD — Defense Sector Read-Through Confirmed (Wednesday). The General Dynamics coverage initiated on Wednesday benefited from a significant amount of positive peer-level intelligence already in the public domain: Lockheed Martin had reported a 10.5% YoY revenue beat of 3.8% against estimates, and RTX had surged on a 14.5% YoY print with a 7.8% consensus beat. The Bihzuun Research analysis correctly framed these peer results as a positive read-through for GD’s own Q2 earnings that morning, and the broad defense earnings cycle validated the structural demand thesis underpinning the defense industrial base coverage. The BRS 4-star Buy rating — reflecting genuine quality in an excellent franchise — was accompanied by candid valuation disclosure that the composite intrinsic value floor sits at approximately $183, roughly 53.5% below the market price. That intellectual honesty is the correct analytical posture for a business priced on long-duration DCF assumptions.
• CBOE — Contrarian Framing Was Analytically Sound. The most conceptually sharp call of the week may prove to be the Cboe analysis published Friday. The central insight — that a 25% drawdown from highs driven by prediction market competition fears fundamentally misread Cboe’s strategic position as an aggressive first mover with regulatory infrastructure, OCC clearing relationships, and broker distribution that fintech entrants lack — is a genuinely differentiated institutional view. Whether the market confirmed this view in Friday’s post-earnings price action remains to be tracked, but the analytical framework was coherent: a perfect historical growth score of 100/100, a 5.8% margin of safety to composite intrinsic value, an EBITDA margin approaching 60%, and a 5-quarter earnings beat track record entered today’s earnings event as the bull case’s evidentiary foundation.

What Didn’t Work (or Carries Unresolved Risk)

• MU — The Fundamental-Momentum Bifurcation Remains Unresolved. The Micron coverage was the week’s most analytically honest and most uncomfortable report to publish. A BRS 4-star Buy rating alongside a −87.2% margin of safety, a BRS Valuation Score of 0/100, and a fundamental target range of $100–$135 against a market price of $900.20 is not a contradiction — it is an explicit acknowledgment that momentum and fundamental value are structurally decoupled in this cycle. The report correctly flagged this bifurcation and offered both a rigorous valuation framework (Graham Number $91.39, EPV $95.63, Comparable Companies $133.86) and a clear explanation of why the market is pricing MU at the DCF scenario ($1,006.95 implied) rather than the fundamental floor. What “didn’t work” is not the analysis — it is that the Bihzuun Value Filter’s normalized intrinsic value framework, by design, resists endorsing cycle-peak extrapolation, and the MU recommendation is therefore inherently split-personality: strong momentum credentials, severe fundamental overvaluation, and a warning that every percentage point of capex intensity in the current up-cycle seeds the next down-cycle’s supply overhang. Investors who followed the momentum posture did well in this cycle. Investors who weighted the fundamental floor did not enter at $900. Both perspectives are represented in the report, and the ambiguity is intentional rather than analytical weakness.
• ANET — Supply Chain Uncertainty Is an Unresolved Thesis Constraint. Arista Networks was covered as a Strong Buy with full conviction on business quality and AI infrastructure positioning, but with an explicit tactical caution: reduce position sizing ahead of the August 4 earnings print, because the Q1 2026 precedent (beat on revenue and EPS; −13.6% next-day reaction on guidance disappointment) demonstrates that the market will not reward headline beats in isolation. Supply chain improvement commentary is what drives the re-rating, not the earnings number itself. As of Friday’s close, this binary remains open and unresolved. If August 4 delivers confirmed supply chain improvement, deferred revenue conversion acceleration, and a Q3 guide at or above $2.95 billion, the Strong Buy thesis will be powerfully validated. If the Q1 pattern repeats, the near-term position will face pressure despite the intact long-term case. This unresolved binary is the most active monitoring item entering next week.
• AZN — China Erosion Is a Real and Ongoing Drag. While the AZN earnings beat was genuine, the 13% China revenue decline in Q2 2026 is not a risk that is being managed away — it is being managed around. Volume-based procurement pressure on the CVRM franchise in China is structural, and the Oncology segment’s partial insulation only goes so far when the world’s second-largest pharmaceutical market is systematically repricing a material portion of AZN’s product portfolio. The thesis is intact, but investors who entered on Monday’s positive earnings headline without internalising the China headwind risk are carrying an incompletely priced position. The Q3 China revenue trajectory update in Q4 2026 will be a critical re-rating decision point.

Portfolio Update

Privacy Note: In accordance with Bihzuun Research’s portfolio reporting standards, no raw dollar figures, share counts, or cost basis information is disclosed. All portfolio commentary is presented in percentage and relative terms only.

The portfolio snapshot provided for this week contained no active position data, indicating that the five names covered this week — AZN, MU, GD, ANET, and CBOE — represent new research coverage initiations rather than additions to an existing active book. This is consistent with Bihzuun Research’s screening and coverage cycle, in which research reports precede position entry and portfolio construction follows independent of publication timing.

Positioning Context by Name

Overall Portfolio Posture

With no active confirmed positions in the snapshot, the portfolio enters the August earnings season in a fully liquid, fully flexible posture. This is analytically appropriate given the density of binary events in the next 30 days: ANET earnings (August 4), July Payrolls (August 7), July CPI (August 12), AZN camizestrant FDA decision (late August), Jackson Hole Symposium (August 27–29), and TMX divestiture regulatory update. Deploying capital aggressively before this sequence of resolved events would be accepting unnecessary binary risk when patience preserves optionality. The five names initiated this week represent the research foundation for a deliberate, event-staged entry programme over the August calendar.

Key Takeaways — Lessons and Patterns from the Week of July 27

• 1. Earnings Day Coverage Amplifies Analytical Signal — But Demands Pre-Event Conviction. Three of the five reports this week were published on, or in proximity to, the subject company’s own earnings event: AZN on Q2 report day (Monday), GD on Q2 report day (Wednesday), and CBOE on Q2 report day (Friday). Publishing research concurrently with an earnings catalyst is simultaneously the most impactful and most exposed analytical posture — the report’s thesis is immediately stress-tested by the market’s response to the same data set. The lesson: pre-event analysis that is grounded in multi-model valuation, identifies the specific data points the market will actually price (not just the headline beat), and maps downside scenarios explicitly is more durable than analysis that arrives after the fact with the benefit of hindsight.
• 2. The Momentum-Value Bifurcation Is a Feature, Not a Bug, of the Current Cycle. Micron’s coverage this week crystallised a pattern that is broader than a single name: the AI infrastructure investment supercycle has created a cohort of businesses in which momentum metrics (growth score 100/100, revenue acceleration, sold-out supply) and value metrics (Graham Number, EPV, margin of safety) point in opposite directions with unusual severity. The Bihzuun Value Filter’s multi-dimensional framework does not resolve this tension by simply ignoring one side — it flags both, assigns differentiated weights by investment horizon, and requires investors to be explicit about which framework they are relying on and why. Investors who are uncomfortable with that ambiguity should restrict their portfolio to the names where fundamental and momentum signals are aligned (AZN, CBOE on a composite basis) rather than bifurcated (MU, ANET at peak multiples).
• 3. Wide Moat Does Not Equal Safe Entry Price — But It Does Define the Floor. AZN’s wide economic moat and GD’s wide and durable moat are analytically confirmed and institutionally credible. But the week’s analysis demonstrated repeatedly that moat width and current price attractiveness are independent variables. GD’s nuclear submarine duopoly, $95 billion backlog, and Gulfstream franchise dominance are beyond dispute — and yet the stock trades at 2.1× its composite fundamental intrinsic value. ANET’s EOS lock-in, 35% ROIC, and hyperscaler preferred-vendor status are equally indisputable — and yet the price-to-sales multiple is at a 10-year peak. Moat quality defines the investment floor under adverse conditions; it does not immunise entry price from mean reversion in a valuation re-rating cycle. Distinguishing between “high quality business” and “attractive investment at current price” is the fundamental discipline this week’s coverage reinforced across multiple names.
• 4. Macro Catalysts Are Not Background Noise — They Are Embedded in Every Valuation Model. The FOMC decision on Wednesday, the Q2 GDP advance estimate on Thursday, and the Jackson Hole setup for August 27–29 appeared in the risk and catalyst sections of every single report this week. This is not coincidental. Interest rates are embedded in discount rates, which are embedded in every DCF. Yield curve steepening affects sector rotation, which affects relative valuations across defense, biopharma, semiconductors, and exchange operators simultaneously. The week was a reminder that even the most rigorous fundamental analysis of a single name operates within a macro regime that can reprice a multiple faster than any operating catalyst can validate an earnings forecast. Monitoring the macro calendar with the same discipline applied to individual earnings events is not optional for institutional-quality portfolio management.
• 5. The Most Asymmetric Opportunities This Week Were the Contrarian Ones. Of the five names covered, the two most asymmetric risk/reward profiles entering next week are arguably the two that received the most skeptical initial market reception: CBOE (down 25% from highs on disruption fears that Bihzuun Research assessed as a strategic misreading) and AZN (trading below its zero-growth Earnings Power Value floor despite a 99th-percentile growth scorecard). The market’s tendency to overprice near-term narrative risk and underprice structural competitive advantage creates the entry windows that the Bihzuun Value Filter is designed to identify. The discipline required is holding that view through the noise of an imminent binary event — and sizing appropriately so that a wrong call in the near term does not eliminate the ability to be right over the medium term.

This publication is produced by Bihzuun Research for educational and research purposes. It does not constitute individualized financial advice. Past research performance does not guarantee future results. All price targets and valuation estimates are analytical outputs subject to revision as new data becomes available. Investors should conduct their own due diligence before making any investment decision.